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Abstract
Background: Optimizing the safety and efficacy of standard chemotherapeutic agents such as cisplatin (CDDP) is
of clinical relevance. Serum starvation in vitro and short-term food starvation in vivo both stress cells by the sudden
depletion of paracrine growth stimulation.
Methods: The effects of serum starvation on CDDP toxicity were investigated in normal and cancer cells by
assessing proliferation, cell cycle distribution and activation of DNA-damage response and of AMPK, and were
compared to effects observed in cells grown in serum-containing medium. The effects of short-term food starvation
on CDDP chemotherapy were assessed in xenografts-bearing mice and were compared to effects on tumor growth
and/or regression determined in mice with no diet alteration.
Results: We observed that serum starvation in vitro sensitizes cancer cells to CDDP while protecting normal cells. In
detail, in normal cells, serum starvation resulted in a complete arrest of cellular proliferation, i.e. depletion of
BrdU-incorporation during S-phase and accumulation of the cells in the G0/G1-phase of the cell cycle. Further
analysis revealed that proliferation arrest in normal cells is due to p53/p21 activation, which is AMPK-dependent
and ATM-independent. In cancer cells, serum starvation also decreased the fraction of S-phase cells but to a minor
extent. In contrast to normal cells, serum starvation-induced p53 activation in cancer cells is both AMPK- and
ATM-dependent. Combination of CDDP with serum starvation in vitro increased the activation of ATM/Chk2/p53
signaling pathway compared to either treatment alone resulting in an enhanced sensitization of cancer cells to
CDDP. Finally, short-term food starvation dramatically increased the sensitivity of human tumor xenografts to
cisplatin as indicated not only by a significant growth delay, but also by the induction of complete remission in
60% of the animals bearing mesothelioma xenografts, and in 40% of the animals with lung carcinoma xenografts.
Conclusion: In normal cells, serum starvation in vitro induces a cell cycle arrest and protects from CDDP induced
toxicity. In contrast, proliferation of cancer cells is only moderately reduced by serum starvation whereas CDDP
toxicity is enhanced. The combination of CDDP treatment with short term food starvation improved outcome
in vivo. Therefore, starvation has the potential to enhance the therapeutic index of cisplatin-based therapy.
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Background
Cisplatin (CDDP) is a standard therapeutic agent for the
treatment of various solid tumors. Its efficacy however
may be limited by patients’ tolerance [1]. The aim of our
investigation was to identify ways to increase the efficacy
of CDDP for cancer killing while enhancing the toler-
ance of normal cells.
Tumor cells are exposed to numerous cellular stresses,
such as oncogene-induced genotoxic stress [2], oxidative
stress [3], and metabolic stress [4], which are not affect-
ing normal cells. Thus, tumor cells are more dependent
on stress support pathways for survival compared to
normal cells. Therapy targeting the stress response
pathways, which can principally be reached through
inhibiting the activity of these pathways or through over-
loading stress to overwhelm these pathways, may be
specifically detrimental to cancer cells while sparing nor-
mal cells [5]. For example it has been shown that
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interfering the cellular response to oxidative stress by a
small molecule selectively kills cancer cells [6], and that
targeting replicative stress response pathway resulted in
specific killing of oncogene-driven tumors [7].
Serum starvation in vitro and short-term food starva-
tion (STS) in vivo have been demonstrated to reduce the
levels of growth factors [8-11]. In normal cells, depletion
of paracrine growth factors reduces the activity of
proliferation-stimulating signaling pathways and reduces
basal cellular metabolism subsequently leading cells to
enter a proliferation-quiescent status [12]. In contrast,
starvation may specifically induce stress in cancer cells
because cancer cells struggle to adapt to the loss of ex-
ternal growth factors by adjusting autonomous growth
stimulation and reprogramming their metabolism thereby
maintaining continuous proliferation [13].
We investigated whether starvation affected the out-
come of CDDP therapy in vitro and in animal models. We
show that serum starvation activates the cellular DNA
damage response pathway specifically in cancer cells. Our
data suggest that starvation has a potential to increase
CDDP-induced toxicity in cancer cells and simultaneously
enhance the tolerance of normal cells to CDDP treatment.
Results
Serum starvation sensitizes ZL55cancer cells to CDDP
FACS analysis of BrdU pulse-labeled ZL55 cancer cells
revealed that the fraction of cells in S-phase were
Figure 1 Serum starvation sensitizes ZL55cancer cells to CDDP. Results of flow cytometry analysis of ZL55 cells untreated (A) or
serum-starved for 24 hours (B) are shown. C, the quantification of flow cytometry results of ZL55 cells of the untreated control, or treated with
CDDP alone, serum starvation alone, or both together is shown (n=3). D, colony formation assay was performed after control treatment (Ctrl),
treatment with CDDP or serum starvation (S) alone, and after the combined treatment (S/CDDP) (n=6, ** p<0.001). The quantification of the
anti-pATM-S1981 immuno-staining of ZL55 cells (** for P<0.001) is shown in (E) (n=3). Results of Western blot with antibodies against
pATM-S1981 (pATM), ATM, phospho Chk2-T68 (pChk2-T68), Chk2 and p53-Ser15 (p53-S15) and p53 for protein extracts are shown in (F).β-Actin
and vinculin were used as loading controls.
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decreased by 40% after 24 hours serum starvation com-
pared to untreated control (Figure 1A-C). BrdU incorp-
oration in starved cancer cells was also reduced
suggesting a reduction of DNA replication in the
remaining S-phase cells (Figure 1B to 1A). When cancer
cells were exposed to CDDP in serum-starved condi-
tions, an increased sensitivity was observed: the com-
bined treatment of CDDP and serum starvation
additively reduced the clonogenicity of human meso-
thelioma ZL55 cells in comparison to either treatment
alone (Figure 1D).
To explore the mechanism of the CDDP sensitization
by serum starvation, the response of cancer cells to
serum starvation was examined in more detail. ATM is
the key component in cellular stress responses to DNA
damage and oxidative stress [14,15]. In ZL55 cells
serum starvation induced a five-fold increase of nuclei
positive for Serine1981-phosphorylated ATM (Ataxia
Telangiectasia Mutated), compared to untreated con-
trol (Figure 1E, and Additional file 1: Figure S1A and
S1C). The starvation-induced activation of ATM in
ZL55 cells was confirmed by Western blot analysis
(Figure 1F), which revealed a 40% increase in phos-
phorylated ATM. Chk2 and p53 are downstream tar-
gets of ATM [14,15]. In addition to the activation of
ATM, enhanced phosphorylation of Chk2 and 50%
Figure 2 Serum starvation-induced activation of ATM/p53 is required for the CDDP sensitization of cancer cells and both ATM and
AMPK are necessary for the activation of p53. Western blot results with antibodies against p53 in protein extracts from ZL55 cells (A) and
HCT116 (B) treated by Ku-55933 (Ku) alone, serum starvation alone, or both together are shown. Results of colony formation assay for the
untreated control HCT116-p53−/− and HCT116-p53+/+ cells and those treated by CDDP alone, serum starvation alone (S), or both together p53-
knockout (n=6, * P<0.02, ** P<0.01, significances were calculated with two-tailed t-Test) are shown in (C). Results of Western blot with antibodies
against pAMPK and AMPK in protein extracts from untreated control ZL55 cells, or treated with CDDP alone or serum starvation alone are shown
in (D). Results of Western blot with antibodies against p53-Ser15 (p53-S15), p53, pACC and ACC in protein extracts from the untreated control
ZL55 cells and those after treatment with Compound C (C.C) alone, CDDP alone, CDDP and C.C together, serum starvation alone, or serum
starvation and C.C together are shown in (E). Results of Western blot with antibodies against phospho-AKT-Ser473 (pAKT) and AKT in protein
extracts from the untreated controlZL55 cells and after treatment with serum starvation alone, Ku55933 alone, serum starvation andKu55933
together, Compound C (C.C) alone, or serum starvation and C.C together are shown in (F). Results of Western blot with antibodies against
phospho-S6-Ser235/236 (pS6) andS6 in protein extracts from the untreated control ZL55 cells and after treatment with serum starvation alone,
Ku55933 alone or Compound C (C.C) alone are shown in (G). β-Actin and vinculin were used as loading controls.
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elevation of p53 protein levels were also observed in
starved ZL55 cells. We noticed that the serine15-
phosphorylation status of p53 in cancer cells is not
affected by serum starvation (Figure 1F).
CDDP-triggered high levels of pATM-S1981 in ZL55
cells, which was further increased significantly (P<0.001)
in the presence of serum starvation (Figure 1E and 1 F,
and Additional file 1: Figure S1B and S1D)resulting in
more than 90% pATM-S1981 positive nuclei under im-
munofluorescent microscopy.
In summary, serum starvation and CDDP both activate
ATM/Chk2/p53 signaling in ZL55 cancer cells and when
combined result in an enhanced activation of the signal-
ing and sensitization of cancer cells to CDDP.
Activation of ATM/p53 is required for the sensitization of
cancer cells to CDDP
The requirement for ATM/p53 activation in the serum
starvation-mediated CDDP sensitization of cancer cells
was examined. We observed that the serum starvation-
induced activation of p53 is ATM-dependent because it
was inhibited by Ku-55933, a specific inhibitor of ATM
[16] (Figure 2A). Similar to the situation in ZL55 cells,
serum starvation resulted in accumulation of p53 in an
ATM-dependent manner in human colorectal cancer
HCT116 cells (Figure 2B). A functional role for p53 in
the serum starvation-mediated CDDP sensitization was
investigated by comparing p53 deficient (p53−/−) versus
p53 proficient (p53+/+) HCT116 cells [17] (functionally
characterized for response to CDDP in Additional file 1:
Figure S2). Serum starvation-induced reduction of clo-
nogenicity was significantly suppressed in p53-deficient
HCT116 cells in comparison to p53-proficient HCT116
cells. The combination of serum starvation and CDDP
further decreased clonogenicity in the p53-proficient
cells, but not in p53-deficient cells (Figure 2C). These
data obtained with the colorectal cancer cells suggest
that the serum starvation-mediated sensitization of can-
cer cells to CDDP is dependent on ATM/p53 activation.
Serum starvation-triggered phosphorylation of AMPK is
required for the stabilization of p53 in cancer cells
AMPK is an important regulator in cellular stress
responses [18] and activates p53 in response to glucose
starvation [19]. The phosphorylation on the Thr-172 of
AMPKα (pAMPK-Thr172) is the crucial step of AMPK
activation [18]. The involvement of AMPK in the cellu-
lar response to serum starvation was examined in cancer
cells. Increased levels of pAMPK-Thr172 were observed
after serum starvation (Figure 2D). In agreement with
the activation of AMPK, elevated phosphorylation of
acetyl-CoA carboxylase (ACC), one of the downstream
targets of AMPK [20], was detected in starved ZL55 cells
as well, which was suppressed in the presence of
compound C, the specific inhibitor of AMPK [21]
(Figure 2E). Compound C inhibited the activation of
p53 induced by both CDDP and serum starvation
(Figure 2E), indicating a general role of AMPK in the
activation of p53 in cancer cells. Consistent with studies
indicating that inhibition of IGF1 signaling is required
for starvation-mediated sensitization of cancer cells
to therapeutic drugs [22,23], we observed a decrease of
AKT phosphorylation upon serum starvation (Figure 2F).
The latter was not affected by ATM inhibitor
Ku55933 or AMPK inhibitor Compound C, indicating
that the inactivation of PI3K pathway and the activa-
tion of p53 by AMPK/ATM are likely independent
mechanisms.
In addition, we verified the possible interference of
ATM and AMPK inhibitors on mTOR signaling by test-
ing their effects on the phosphorylation of S6, which is a
target downstream of mTOR. While serum starvation
strongly inhibited the phosphorylating of S6, ATM
inhibitor Ku55933 and AMPK inhibitor Compound C
did not show any effect on the S6 phosphorylation
(Figure 2G), suggesting that ATM inhibitor (Ku55933)
and AMPK inhibitor (Compound C) were quite target-
specific and do not interfere activity of mTOR signaling.
Short-term food starvation sensitizes human
mesothelioma xenografts to CDDP
To investigate combined effect of starvation with CDDP
in vivo, short-term food starvation (STS) was implemen-
ted [22-24]. ZL55 cells were subcutaneously injected into
nude mice. Tumor-bearing animals were treated with
the standard dose of CDDP (3 mg/kg) in the presence or
absence of STS, or with STS alone once per week for
three weeks. No significant inhibition of tumor growth
was observed when CDDP was administrated alone. A
mild (P<0.05) delay of tumor growth by STS alone was
observed (Figure 3A). However, a dramatic (P<0.01) in-
hibition of tumor growth was observed when mice were
treated with the combination of CDDP and STS. The
average tumor volume was reduced by more than 60%
three weeks after treatment, compared with untreated
controls (Figure 3A). Tumors continued growing for
4 weeks after ending of the combination treatment.
Then, tumors started to regress. During the 8th to 10th
week after the treatment, complete remission was
observed in 60% combination-treated animals. Animals
with complete tumor remission were kept for additional
at least 4 weeks, and no recurrence was observed. No re-
mission was observed in any other groups at the end of
a 16 weeks follow-up period (Figure 3B).
Animals lost 15% in average body weight during STS,
but they regained most of the lost body weight during
the next day after STS (Additional file 1: Figure S3).No
apparent effect on the evolution of body weight was
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observed overlong term duration (Figure 3C). Thus, our
data suggest that STS with water ad libitum is tolerable
for animals and strongly sensitizes mesothelioma tumors
to CDDP in vivo.
STS sensitizes human lung carcinoma A549 xenografts to
CDDP
We extended our in vitro and in vivo observations on
human mesothelioma cells to human lung adenocarcin-
oma cells (A549). As observed in ZL55 cells, serum star-
vation of A549 cells did trigger Chk2 activation, p53
accumulation and phosphorylation of histone H2AX (γ-
H2AX), which is also an ATM target (Figure 4A). How-
ever, activation of ATM and AMPK was not detectable
(data not shown). This might be due to different kinetics
in ZL55 versus A549 cells. Indeed, in serum-starved
ZL55 cells at the same time point there was no differ-
ence in phospho-H2AX levels compared to untreated
control. We examined the sensitization of A549-derived
xenografts to CDDP by STS in vivo as well. No signifi-
cant effect on tumor growth by STS or CDDP alone was
observed (Figure 4B). However, the combined treatment
with CDDP and STS resulted in 65% reduction of tumor
burden three weeks after treatment (Figure 4B) and
complete remission of tumors without recurrence in
40% of animals treated with the combination. No
complete remission occurred in any other groups at the
end of the 40 weeks follow-up period (Figure 4C).
Therefore, STS also sensitizes human lung adenocarcin-
oma xenografts to CDDP.
In normal cells serum starvation results in proliferation
arrest and protection against CDDP toxicity
We used cultured primary human mesothelial SDM104
cells to investigate the effects of serum starvation on the
response of normal cells to CDDP. In contrast to cancer
cells where serum-starvation only partially reduced S-
phase cells, FACS analysis of SDM104 cells showed that
Figure 3 Starvation sensitizes human mesothelioma xenografts to CDDP in vivo.. A, growth curves of ZL55 tumors in the untreated control
animal group and those treated with CDDP, STS, or both together (n=5/group) (* P<0.05; ** P<0.01). B, complete tumor remission is observed
only with the combined treatment. C, curves of average body weight of animals with ZL55 tumors in different groups during and after the
treatments. Arrows in (A) and (C) indicate the time points of individual treatments.
Figure 4 Starvation sensitizes human lung carcinoma A549 xenografts to CDDP in vivo. A, Western blot results with antibodies against
phospho Chk2-T68, Chk2, γ-H2AX and p53 for protein extracts from untreated control A549 cells and those treated with CDDP alone, serum
starvation alone, or both together are shown. β-Actin was used as loading control. B, growth curves of A549 tumors in the untreated control
animal group and those treated with CDDP, STS, or both together (n=6/group) (** P<0.011). C, complete tumor remission is observed only with
the CDDP treatment combined with STS. The arrows in (B) indicate the time points of individual treatments.
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serum starvation alone (24 hours) resulted in complete
abolishment of S-phase (BrdU-positive) cells and induc-
tion of a cell cycle arrest in G0/G1-phase, compared
with untreated control (Figure 5A-C). Survival of
SDM104 cells growing in the continuous presence of
serum was reduced by 74% by CDDP treatment com-
pared to untreated control cells (Figure 5D). In contrast,
survival of serum starved SDM104 cells after exposure
to CDDP was reduced only by 55% compared to
untreated control cells, which was similar to reduction
in survival observed after serum starvation alone,
indicating a significant (P<0.002) increase of CDDP tol-
erance induced by serum starvation in normal SDM104
cells. The serum starvation-mediated protective effects
from CDDP toxicity were also observed in two add-
itional normal primary human cell cultures (Additional
file 1: Figure S4).
In agreement with the ATM activation status, CDDP
exposure induced activation of p53 (phosphorylation and
protein accumulation) and p21 accumulation (Figure 5E
and 5F). Consistent with the increased CPPD tolerance of
serum-starved normal cells, CDDP-induced activation of
Figure 5 Serum starvation induces proliferation arrest in normal SDM104 cells and protects them from CDDP cytotoxicity in vitro. Flow
cytometry analysis of SDM104 cells of untreated (A) or serum-starved for 24 hours (B). C, the quantification of flow cytometry results of SDM104
cells of the untreated control, or treated with CDDP alone, serum starvation alone, or both together is shown (n=3). D, MTT assays (n=6) were
performed to examine the viability of SDM104 cells of the untreated control and those treated by CDDP alone, serum starvation alone (S), or
both together in vitro (** P<0.002). E, the quantification of the results of anti-pATM-Ser1981 immuno-staining in SDM104 cells of untreated
control, treated by CDDP alone, serum starvation alone, or both together is shown (** P<0.002, n=3). F, Western blot results with antibodies
against pATM-Ser1981 (pATM), p53-Ser15 (p53-S15), p53 and p21 in protein extracts from the untreated control, or treated with CDDP alone,
serum starvation alone, or both together are shown. G, Western blot results with antibodies against pAMPK, AMPK, p53, p21, pACC and ACC in
protein extracts from untreated control, treated with Compound C (C.C) alone, serum starvation alone, or both together. β-Actin and vinculin
were used as loading controls.
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ATM was suppressed by serum starvation (Figure 5E and
5F, and Additional file 1: Figure S5B and S5D). Although
serum starvation alone did not induce activation of ATM,
it triggered accumulation of p53 and the cell cycle inhibi-
tor p21 (Figure 5F).
In order to investigate the mechanism responsible for
p53 and p21 activation upon serum-starvation, we tested
whether AMPK was activated by serum starvation in
normal cells as well. Serum starvation induced pAMPK-
Thr172 in SDM104 cells, which was confirmed by
the increased phosphorylation of ACC (Figure 5G). The
serum starvation-induced accumulation of p53 and the
up-regulation of p21 in normal cells were inhibited by
the AMPK inhibitor compound C (Figure 5G), suggest-
ing that activation of AMPK is required for serum
starvation-induced upregulation of p53 and p21. To-
gether, these results demonstrate that serum starvation
induces in normal cells the activation of AMPK thereby
initiating a p53/p21-mediated proliferation arrest, which
confers resistance to CDDP-induced cytotoxicity.
Discussion
Our study reveals that serum starvation sensitizes cancer
but not normal cells to CDDP treatment. Indeed, serum
starvation activates in cancer but not normal cells ATM/
Chk2/p53 signaling pathway. The latter is also activated,
as expected, after CDDP treatment. Challenging serum
starved cancer cells with CDDP triggers the hyper-
activation of ATM/Chk2/p53 signaling resulting in
sensitization of cancer cells to CDDP (Figure 6). This
observation is in line with the recently developed con-
cept that overloading stress may exhaust the cellular
stress response pathways thereby sensitizing cancer cells
to chemotherapy [5].
One of the potential reasons for ATM/Chk2/p53 acti-
vation by serum starvation may be due to a temporary
loss of coordination between the cell proliferation
driven by oncogenic mutations and the paracrine growth
factors–stimulated cell growth, thus resulting in cellular
stress. For example, proliferation in the absence of
serum is known to lead to depletion of the nucleotide
pool [25], and the latter has been associated with altered
DNA replication dynamics and genomic instability
which trigger the activation of DNA damage response
[26]. In this context it is noteworthy that pemetrexed, an
agent known to deplete nucleotide pools in cancer cells
[27], improves the efficacy of CDDP therapy in the clinic
[28,29].
Another possibility for ATM/Chk2/p53 activation by
serum starvation is the induction of oxidative stress,
which directly oxidizes ATM thereby being independent
of DNA damage induction [15]. However, serum starva-
tion did not induce the general oxidative stress marker
heme oxygenase-1 [30] in both ZL55 and A549 cancer
cell lines tested (Additional file 1: Figure S6), ruling out
oxidative stress being involved in starvation-induced
CDDP sensitization. Nevertheless, this mechanism
could possibly be responsible for ATM activation in
HCT116 cells where low expression levels of the ATM-
activating MRN-complex protein MRE11 have been
described [31,32]. Understanding the mechanism of
serum starvation-induced ATM activation in cancer cells
is beyond the scope of the present study and future work
will address this issue.
It is noteworthy that serum starvation in cancer cells
induced ATM and AMPK-mediated stabilization of p53
only, whereas CDDP treatment triggered both phosphor-
ylation of p53 at Ser15 and stabilization of the protein.
Although Ser15 phosphorylation generally stabilizes
the p53 protein, Ser15-phosphorylation-unrelated p53
stabilization has also been reported and potential
mechanisms include acetylation and methylation. How-
ever, an acetylation-dependent mechanism was excluded
because of the absence of change of the Lys373 and
Lys320 acetylation status of p53 under starvation condi-
tion (data not shown). Methylation dependent mechan-
isms remain to be explored.
In contrast to cancer cells, serum starvation-activated
AMPK triggers in normal cells the stabilization of p53
Figure 6 Starvation selectively sensitizes human cancer cells to
CDDP. In normal cells, serum starvation activates AMPK, which
stabilizes p53 resulting in cell proliferation arrest. The processing of
CDDP-DNA-adducts in proliferating cells results in DNA damage.
Proliferation arrest may contribute to the inactivation of DNA
damage response thus the tolerance of normal cells to CDDP. In
cancer cells, serum starvation also activates ATM/Chk2/p53 signaling.
The combination of CDDP with serum starvation results in the
enhanced activation of the signaling and sensitizes cancer cells
to CDDP.
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and elevation of p21 thus resulting in a cell cycle arrest.
It is known that DNA replication is blocked by CDDP-
DNA-adducts, which can lead to DNA replication fork
breakdown and subsequent DNA damage accumulation
in replicating cells [33,34]. Therefore, the observed re-
duction in DNA replication upon serum starvation can
explain the enhanced CDDP tolerance in normal cells
(Figure 6). Consistently, DNA damage response is not
activated after CDDP treatment in serum-starved nor-
mal cells.
The outcome of combined STS/CDDP treatment, i.e.
tumor growth delay and/or tumor eradication, is similar
to a recent observation by Lee et al., where sensitization
of cancer cells to several chemotherapeutic drugs was
induced by low glucose and low serum level in vitro and
STS in vivo. Inhibition of IGF1 signaling was required
for starvation-mediated protection of normal cells and
sensitization of cancer cells to therapeutic drugs [22,23].
We show here an additional mechanism mediated by
the negative regulatory signaling of AMPK, which is
activated under stress conditions, e.g. nutrient starva-
tion, to suppress proliferation [35]. We observed that
serum starvation activated AMPK in both cancer and
normal cells. Additionally, AMPK activity was necessary
for the stabilization of p53 in response to serum starva-
tion in both cancer and normal cells. Thus, our study
reveals that in addition to the inhibition of proliferation-
enhancing IGF1 signaling pathway, the activation of the
AMPK signaling cascade, which suppresses proliferation,
is also involved in the starvation-induced protection of
normal cells and sensitization of cancer cells to CDDP
treatment.
Although the design of our in vivo study does not
allow extrapolating that the same mechanisms observed
in vitro are operative in vivo, we nevertheless observed
that STS sensitized xenografts of mesothelioma and lung
cancer to CDDP treatment. Prolonged fasting is now
implemented in the treatment of several diseases includ-
ing rheumatic diseases and chronic pain syndromes [36],
indicating beneficial effects [36]. In the context of cancer
treatment, STS is well-tolerated in animal models and
reduces the side effects of various chemotherapy regi-
mens [22,24]. A case series report suggested that STS
may also be applicable to cancer patients [37].
Conclusions
In normal cells, serum starvation-activated AMPK stabi-
lizes p53 and p21 resulting in a proliferation arrest.
Serum starvation thereby protects normal cells from
CDDP toxicity. In cancer cells, serum starvation add-
itionally activates the ATM/Chk2/p53 stress response
signaling pathway, which is also induced by CDDP
treatment. The function of AMPK is required for
maintaining this signaling. Therefore, combining CDDP
treatment with serum starvation results in the hyper-
activation of ATM/Chk2/p53 signaling pathway, thus
sensitizing cancer cells to CDDP. In line with these
in vitro observations, combining CDDP treatment with
short-term food starvation in vivo delays tumor growth
and induces tumor regression. Thus, our study indicates
that STS may enhance the efficacy of CDDP-based
chemotherapy.
Methods
Cell Cultures and Reagents
Human mesothelioma ZL55 [38], lung carcinoma A549
[39] cells, the colorectal carcinoma cell lines HCT116
40.16 (p53+/+) and HCT116 379.2 (p53−/−) [17], and
primary normal human mesothelial SDM104 [40] cells
were cultured in M199 (Invitrogen)/MCDB106 (Sigma)
(1:1) mixed medium supplemented with 15% FCS,
10 ng/ml EGF, and 0.4μg/ml hydrocortisone as described
[41]. The M199/MCDB106 medium without supple-
ments was used for serum starvation assays. All cell lines
used in this study were authenticated by fingerprinting
(Microsynth, Balgach, Switzerland). CDDP (1667 μM sa-
line solution, EbewePharma) was used for all in vitro
and in vivo experiments. The CDDP concentration was
8 μM for all in vitro experiments unless otherwise indi-
cated. For the in vitro treatments, cells were incubated
with CDDP for 16 hours. Ku55933 and Compound C
(Merck) were used at concentrations of 5 μM and
20 μM, respectively. To investigate the effects of serum
starvation, CDDP treatment started 8 hours after the be-
ginning of serum starvation and lasted 16 hours in star-
vation medium. Colony formation assays and MTT cell
proliferation assay were performed as described [42,43].
Due to their limited growth ability, proliferation of nor-
mal cells was examined with MTT assay.
Immunostaining and Western blot
For immunostaining, cells were fixed with 4% formalde-
hyde in PBS for 20 minutes in room temperature.
Permeabilization was done with 100% methanol at 4°C
for 4 minutes. The incubations with the first and the
secondary antibodies were done at room temperature
for 2 and 1 hours, respectively. Stained cells were
mounted with Prolong Gold Anti-fade reagent with 40,6
–diamidino-2-phenylindole (Invitrogen). Images were
taken with an inverse wide-field fluorescence microscope
(Leica). Anti-ATM-Ser1981 antibody (Cell Signaling)
for immunostaining, anti-ATM-Ser1981 (Epitomics) for
Western, anti-ATM (2C1) (GeneTex), anti-Akt, anti-
phospho-Akt (Ser473), anti-phospho-AMPKα (Thr172)
(40H9), anti-AMPKα, anti-Chk2, anti-phospho-p53-Ser15,
anti-S6and anti-phospho-S6 (Cell Signaling), anti-phospho-
Chk2-T68 (R&D System), anti-phospho-H2AX (γ-H2AX)
(Millipore), anti-p53 and anti-p21 (Santa Cruz) were used
Shi et al. BMC Cancer 2012, 12:571 Page 8 of 10
http://www.biomedcentral.com/1471-2407/12/571
according to the product instructions. Western blot ana-
lysis was performed as described [44]. For Western against
ATM, protein extracts were run in 5% SDS-polyacrylamide
gel while the rest were run in 13.5% SDS-polyacrylamide
gel. Western blots were quantified using ImageJ.
Flow cytometry (FACS) analysis
Before harvesting, cells were exposed to 10 μM BrdU for
one hour. FACS samples were prepared as described
[45]. After anti-BrdU antibody (BD Biosciences) and
propidium iodide (PI) (Sigma) staining, FACS was per-
formed with FACS Calibur (FACScan, BD Biosciences)
and data was analysed with Summit v4.3software.
In vivo experiments
All animal experiments were approved by Kantonales
Veterinätamt Zürich and performed in accordance with
the ethical principles and guidelines for experiments on
animals of Swiss Academy of Medical Sciences. 8 week-
old CD1 female nude mice (Charles River and Harlan)
were randomly divided into groups. ZL55 cancer cells or
A549 cancer cells in 100 μl PBS (0.5x106 cells per ani-
mal) were subcutaneously injected into the left flank side
of the mice. Tumor volume was measured by calliper
and calculated with the formula: Width2×Length/2 [46].
Tumor growth in untreated animals was used as control.
Treatments started when the tumor volumes reached 30
±17 mm3. CDDP (3 mg/kg) was injected i.p. once per
week for three weeks. Short-term fasting was implemen-
ted 32 hours prior and 16 hours post-injection with
water ad libitum. During the treatment, animals were
monitored routinely for body weight loss and general be-
haviour. Tumor growth and animal weight were
recorded once per week for at least 16 weeks. Animals
were sacrificed when any of the following signs for se-
vere suffering was observed: the tumor volume reached
500 mm3; body weight loss was observed for 4 consecu-
tive days; loss of more than 15% body weight; sign of se-
vere sickness, for example, reduced mobility and eating,
ruffled hair, and hunched back posture.
Statistical analysis
Mann–Whitney or two-tailed t-Test was performed.
Additional file
Additional file 1: Figure S1. Serum starvation and CDDP both
activate ATM in ZL55 cancer cells and when combined result in an
enhanced activation of the ATM. Anti-phosphoATM-Ser1981 (pATM)
immuno-staining of untreated ZL55 cells (A) and those treated with 8 μM
CDDP alone (B), serum starvation alone (C), or both together (D) are
shown. In (A-D), images of anti-pATM staining (in red) are in left, and
images of DAPI staining in middle while on the right are the overlap. “S”
in (C) and (D) stands for serum starvation. Figure S2. p53 is knockout in
HCT116p53−/−cells. No p53 was detected in the protein extract from
CDDP-treated HCT116p53−/− cells while it was induced in p53-proficient
HCT116 cells. β-Actin was used as loading control. Figure S3. STS with
water ad libitum is tolerable for animals. Animals regained most of the
lost body weight during the next day after starvation. Figure S4. Serum
starvation protects normal cells from CDDP cytotoxity. MTT assays were
performed after primary normal cell cultures LP9, SDM104 and SDM85,
which was established from a normal pleural tissue received from a
patient undergoing cancer unrelated thoracic surgery (this study was
approved by the Zurich University Hospital ethic committee and a
written informed consent was obtained from the patient), were treated
with CDDP alone, serum starvation alone or both together (* for P<0.002;
** for P<3.0x10-5). CDDP8 and CDDP20 stands for 8 μM and 20 μM CDDP,
respectively. Figure S5. Serum starvation suppressed the CDDP-induced
activation of ATM in normal cells. Anti-phosphoATM-Ser1981 (pATM)
immuno-staining of untreated SDM104 cells (A) and those treated with
8 μM CDDP alone (B), serum starvation alone (C), or both together (D)
are shown. In (A-D), images of anti-pATM staining (in red) are in left, and
images of DAPI staining in middle while on the right are the overlap. “S”
in (C) and (D) stands for serum starvation. Figure S6. Serum starvation
does not induce the expression of oxidative stress marker, HO-1 in ZL55
and A549 cancer cells. Western blot results with antibodies against HO-1
for protein extracts from untreated control and those treated with CDDP
alone, serum starvation alone, or both together are shown for ZL55 (A)
and A549 (B) cells. β-Actin was used as loading control.
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